Avrobio (AVRO) has disclosed a new risk, in the Share Price & Shareholder Rights category.
AVROBIO’s strategic shift and merger with Tectonic will place the entity into a regulatory landscape fraught with complexities. The disposal of its historical assets and cessation of its gene therapy programs positions AVROBIO as a reporting shell company, subjecting it to stringent SEC requirements. The implications are significant: extended timelines for utilizing certain forms, a prohibition on well-known seasoned issuer status for three years, and restrictions on the sale of securities. This regulatory environment is likely to increase the cost and time associated with capital raising and compliance for the newly formed public entity.
The average AVRO stock price target is $2.00, implying 62.60% upside potential.
To learn more about Avrobio’s risk factors, click here.
